Agilon Health (NYSE:AGL – Get Free Report) and Charles River Laboratories International (NYSE:CRL – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.
Profitability
This table compares Agilon Health and Charles River Laboratories International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Agilon Health | -6.09% | -146.03% | -24.55% |
| Charles River Laboratories International | -4.59% | 15.36% | 6.61% |
Valuation & Earnings
This table compares Agilon Health and Charles River Laboratories International”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agilon Health | $5.82 billion | 0.23 | -$391.35 million | ($21.56) | -3.72 |
| Charles River Laboratories International | $4.02 billion | 1.91 | -$144.34 million | ($3.76) | -42.31 |
Charles River Laboratories International has lower revenue, but higher earnings than Agilon Health. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Agilon Health and Charles River Laboratories International, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agilon Health | 3 | 7 | 5 | 0 | 2.13 |
| Charles River Laboratories International | 1 | 4 | 11 | 0 | 2.63 |
Agilon Health currently has a consensus price target of $52.50, suggesting a potential downside of 34.55%. Charles River Laboratories International has a consensus price target of $205.86, suggesting a potential upside of 29.40%. Given Charles River Laboratories International’s stronger consensus rating and higher probable upside, analysts plainly believe Charles River Laboratories International is more favorable than Agilon Health.
Institutional and Insider Ownership
98.9% of Charles River Laboratories International shares are owned by institutional investors. 2.3% of Agilon Health shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Agilon Health has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.
Summary
Charles River Laboratories International beats Agilon Health on 10 of the 14 factors compared between the two stocks.
About Agilon Health
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
About Charles River Laboratories International
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Receive News & Ratings for Agilon Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilon Health and related companies with MarketBeat.com's FREE daily email newsletter.
